NWBO Seeks 53% Stock Authorization Hike, Board Election at Annual Meeting

TL;DR

**NWBO's massive stock authorization request smells like dilution bait; vote against it unless you want your shares watered down.**

AI Summary

Northwest Biotherapeutics, Inc. (NWBO) is holding its Annual Meeting of Stockholders on December 29, 2025, to address several key proposals. The company seeks to elect Mr. Pat Sarma as a Class II Director for a three-year term expiring in 2028. Stockholders will also vote on the ratification of Cherry Bekaert LLP as the independent registered public accounting firm for fiscal year 2025. A significant proposal involves approving an amendment to the Certificate of Incorporation to increase authorized common stock from 1,700,000,000 to 2,600,000,000 shares, representing a 52.9% increase. Additionally, an advisory vote on executive compensation will take place. As of November 14, 2025, NWBO had 1,528,682,082 shares of common stock and 818,142 shares of preferred stock outstanding, with each preferred share convertible into 25 common shares. The company is bearing the estimated $80,000 cost of proxy solicitation by Georgeson LLC.

Why It Matters

This DEF 14A filing is crucial for NWBO investors as it outlines a significant proposed increase in authorized common stock from 1.7 billion to 2.6 billion shares. Such an increase could signal future capital raises, potentially diluting existing shareholder value, or provide flexibility for strategic acquisitions and employee incentives. The election of Mr. Pat Sarma to the board and the advisory vote on executive compensation also offer insights into corporate governance and management alignment with shareholder interests. In the competitive biotech landscape, the ability to raise capital efficiently is paramount for drug development, making this authorization increase a key indicator of NWBO's strategic financial planning.

Risk Assessment

Risk Level: high — The proposal to increase authorized common stock from 1,700,000,000 to 2,600,000,000 shares represents a substantial 52.9% potential increase in share count. This significant authorization could lead to substantial future dilution for existing shareholders if the company issues new shares, impacting per-share value and voting power.

Analyst Insight

Investors should carefully evaluate the proposed increase in authorized common stock and consider its potential dilutive effects. Engage with the company to understand the specific rationale and intended use of the additional shares before the December 29, 2025 meeting. Vote on all proposals, especially the stock authorization, to protect your investment.

Key Numbers

• 2,600,000,000 — Proposed authorized common stock (Increase from 1,700,000,000 shares)
• 1,700,000,000 — Current authorized common stock (Proposed to increase to 2,600,000,000 shares)
• 1,528,682,082 — Common stock outstanding (As of November 14, 2025)
• 818,142 — Preferred stock outstanding (As of November 14, 2025, each convertible into 25 common shares)
• $0.001 — Par value per share (Common Stock)
• $80,000 — Estimated cost of proxy solicitation (Paid to Georgeson LLC)
• 25 — Common shares per preferred share (Conversion rate for preferred stock)
• 2025-12-29 — Annual Meeting Date (Date of the 2025 Annual Meeting of Stockholders)
• 2025-11-14 — Record Date (Stockholders of record entitled to vote)
• 52.9% — Percentage increase in authorized shares (From 1.7 billion to 2.6 billion shares)

Key Players & Entities

• NORTHWEST BIOTHERAPEUTICS INC (company) — Registrant
• NWBO (company) — Ticker
• Linda F. Powers (person) — Chairperson of the Board of Directors, President, CEO, CFO, CAO
• Pat Sarma (person) — Nominee for Class II Director
• Cherry Bekaert LLP (company) — Independent registered public accounting firm
• Georgeson LLC (company) — Proxy solicitation agent
• Gibson, Dunn & Crutcher LLP (company) — Location of Annual Meeting
• Securities and Exchange Commission (regulator) — Filing oversight
• Dr. Alton L. Boynton (person) — Class I Director, Chief Scientific Officer and Secretary
• Dr. Navid Malik (person) — Class III Director

FAQ

Industry Context

Northwest Biotherapeutics operates in the biotechnology sector, focusing on the development of cancer immunotherapies. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Success often hinges on clinical trial outcomes and the ability to secure substantial funding for ongoing research and commercialization efforts.

Regulatory Implications

The company's operations are subject to stringent regulations by bodies like the FDA. Any delays or failures in clinical trials or manufacturing processes can have significant financial and reputational consequences. The proposed increase in authorized shares may also be viewed by regulators and investors in the context of the company's financial health and future funding needs.

What Investors Should Do

1. Vote on the proposed increase in authorized common stock from 1,700,000,000 to 2,600,000,000 shares, as this significantly impacts potential future dilution.
2. Review the proposal to elect Mr. Pat Sarma as a Class II Director and consider his qualifications and alignment with shareholder interests.
3. Consider the ratification of Cherry Bekaert LLP as the independent auditor, ensuring confidence in the company's financial reporting.
4. Evaluate the advisory vote on executive compensation, assessing whether it aligns with company performance and shareholder value.

Key Dates

• 2025-12-29: Annual Meeting of Stockholders — Date for voting on key proposals including director election, auditor ratification, and stock authorization increase.
• 2025-11-14: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting.
• 2025-11-29: Mailing of Proxy Materials — Indicates when stockholders can expect to receive the proxy statement and related documents.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that must be filed by companies when they are soliciting proxies from shareholders for their annual meeting. (This document contains the information presented in this analysis, detailing the proposals and information relevant to the annual meeting.)

Certificate of Incorporation

The foundational legal document that establishes a corporation and outlines its basic structure, purpose, and powers. (An amendment to this document is proposed to increase the authorized shares of common stock.)

Independent registered public accounting firm

A firm of certified public accountants that is independent of the company and is engaged to audit the company's financial statements. (Stockholders will vote on ratifying Cherry Bekaert LLP as the company's auditor for fiscal year 2025.)

Proxy solicitation

The process by which a company requests shareholders to grant authority (a proxy) to someone to vote their shares on their behalf at a shareholder meeting. (The company is incurring costs for this process, hiring Georgeson LLC.)

Year-Over-Year Comparison

This filing does not provide direct comparative data to a previous filing for metrics like revenue or net income. However, the significant proposal to increase authorized shares by 52.9% suggests a strategic move to facilitate future financing or operational needs, which may indicate a different financial outlook or capital requirements compared to previous periods.

Key Financial Figures

• $0.001 — 700,000,000 to 2,600,000,000, par value $0.001 per share (the "Common Stock"); 4.
• $80,000 — red by Georgeson LLC is estimated to be $80,000, plus reimbursement of reasonable out-o

Filing Documents

• tm2530047-1_def14a.htm (DEF 14A) — 428KB
• lg_georgesonric-4clr.jpg (GRAPHIC) — 24KB
• bc_captsr-4clr.jpg (GRAPHIC) — 67KB
• bc_netincome-4clr.jpg (GRAPHIC) — 91KB
• px_25northwestprox1pg1-bw.jpg (GRAPHIC) — 251KB
• px_25northwestprxy1pg2-bw.jpg (GRAPHIC) — 276KB
• 0001104659-25-116966.txt ( ) — 2819KB
• nwbo-20241231.xsd (EX-101.SCH) — 9KB
• nwbo-20241231_lab.xml (EX-101.LAB) — 33KB
• tm2530047-1_def14a_htm.xml (XML) — 146KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 12 CORPORATE GOVERNANCE MATTERS 14

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 17 PRINCIPAL ACCOUNTANT FEES AND SERVICES 29 OTHER MATTERS 30 ADDITIONAL INFORMATION 31 APPENDIX A A-1 i TABLE OF CONTENTS NORTHWEST BIOTHERAPEUTICS, INC. 4800 Montgomery Lane Suite 800 Bethesda, Maryland 20814 PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 29, 2025 This proxy statement is being furnished in connection with the solicitation of proxies by the Board of Directors of Northwest Biotherapeutics, Inc. ("we," "us," "our" or the " Company ") for use at the Annual Meeting of Stockholders (the " Annual Meeting "), to be held on Monday, December 29 at 2:00 p.m. Eastern Time, and any adjournments or postponements of the Annual Meeting. The Board of Directors, or the " Board ," is soliciting proxies for the purposes set forth in the accompanying Notice of the Annual Meeting of Stockholders. Record Date and Share Ownership Only stockholders of record on our books at the close of business on November 14, 2025 will be entitled to attend and vote at the Annual Meeting and any adjournments or postponements of the Annual Meeting. As of the close of business on November 14, 2025, we had 1,528,682,082 shares of common stock outstanding and 818,142 shares of preferred stock outstanding. Each share of common stock entitles the record holder to one vote on each matter to be voted upon at the Annual Meeting. Each share of preferred stock is convertible into 25 shares of common stock and hence entitles the record holder to 25 votes on each matter to be voted upon at the Annual Meeting. Copies of the Notice of the Annual Meeting of Stockholders, this proxy statement, the enclosed proxy card and the 2024 Annual Report are expected to be mailed to stockholders of record on or about November 29, 2025. Exhibits to the 2024 Annual Report will be provided to any stockholder at no charge upon written or oral request to our corporate secretary at the address set forth under " Communication wi